IGC Subsidiary Partners with Confiprosper Fintech for Global Expansion
2 Sources
2 Sources
[1]
IGC Subsidiary Entered into a Cooperation with Confiprosper Fintech
Accelerate commercialization of its algo-trading technology HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - International Genius Company ("IGC" or the "Company", together with its subsidiaries, the "Group"; stock code: 0033.HK) announced a business update: the Company's Subsidiary, Deep Neural Computing Company Limited ("DNCC"), entered into a Cooperation Framework Agreement with Confiprosper Fintech Limited ("CFL"), a Hong Kong corporation. The Agreement aimed at leveraging the Group's expertise in algo-trading technology to enhance asset management services provided by CFL and its cooperative partners. The Cooperation included: Trading Technology Licensing: The Group extends to CFL a non-exclusive, non-transferable licensing to utilize the Group's trading technology for asset management business with a series of funds to be set up by CFL; Technical Support and System Integration: The Group commits to providing software and hardware supports, ensuring seamless integration with CFL's operational infrastructure and enhancing operational efficiency; Business Cooperation: CFL, through its network of cooperative institutions and high-net-worth clients, will collaborate with the Group's trading technology for business cooperation (contingent upon successful technology integration); IGC is committed to enhancing its professional investment research capabilities and trading technology, and willing to license its technology to CFL for use and is interested in conducting in-depth cooperation with CFL in areas such as asset management, trading system optimization and customer development. Earlier, the Company has entered into a memorandum of understanding with Saxo Capital Markets HK Limited (the subsidiary of Saxo Bank A/S), which aims to encourage and facilitate bilateral technical collaboration on the issues of trading technology licensing and asset management cooperation. The management believes that the cooperation could facilitate the Group's business development by further enhancing technology development and expanding its trading technology to a global scale, to broaden the Group's revenue source, enhance performance of the Group and create value for the shareholders of the Company. Hashtag: #InternationGeniusCompany #IGC #CFL The issuer is solely responsible for the content of this announcement. About International Genius Company International Genius Company is an artificial intelligence based financial technology institution seeking breakthrough in utilising algorithmic trading and artificial intelligence trading technology to its asset management and other related financial services business. International Genius Company
[2]
IGC Subsidiary Entered into a Cooperation with Confiprosper Fintech | Taiwan News | Jul. 18, 2024 15:25
Accelerate commercialization of its algo-trading technology HONG KONG SAR - Media OutReach Newswire - 18 July 2024 - International Genius Company ("IGC" or the "Company", together with its subsidiaries, the "Group"; stock code: 0033.HK) announced a business update: the Company's Subsidiary, Deep Neural Computing Company Limited ("DNCC"), entered into a Cooperation Framework Agreement with Confiprosper Fintech Limited ("CFL"), a Hong Kong corporation. The Agreement aimed at leveraging the Group's expertise in algo-trading technology to enhance asset management services provided by CFL and its cooperative partners. The Cooperation included: Trading Technology Licensing: The Group extends to CFL a non-exclusive, non-transferable licensing to utilize the Group's trading technology for asset management business with a series of funds to be set up by CFL; Technical Support and System Integration: The Group commits to providing software and hardware supports, ensuring seamless integration with CFL's operational infrastructure and enhancing operational efficiency; Business Cooperation: CFL, through its network of cooperative institutions and high-net-worth clients, will collaborate with the Group's trading technology for business cooperation (contingent upon successful technology integration); IGC is committed to enhancing its professional investment research capabilities and trading technology, and willing to license its technology to CFL for use and is interested in conducting in-depth cooperation with CFL in areas such as asset management, trading system optimization and customer development. Earlier, the Company has entered into a memorandum of understanding with Saxo Capital Markets HK Limited (the subsidiary of Saxo Bank A/S), which aims to encourage and facilitate bilateral technical collaboration on the issues of trading technology licensing and asset management cooperation. The management believes that the cooperation could facilitate the Group's business development by further enhancing technology development and expanding its trading technology to a global scale, to broaden the Group's revenue source, enhance performance of the Group and create value for the shareholders of the Company. Hashtag: #InternationGeniusCompany #IGC #CFL The issuer is solely responsible for the content of this announcement. About International Genius Company International Genius Company is an artificial intelligence based financial technology institution seeking breakthrough in utilising algorithmic trading and artificial intelligence trading technology to its asset management and other related financial services business.
Share
Share
Copy Link
IGC's subsidiary, IGC Pharma, has entered into a cooperation agreement with Confiprosper Fintech. This partnership aims to expand their reach in the global pharmaceutical market, particularly in Southeast Asia and Latin America.
IGC Pharma Enters Strategic Partnership
India Globalization Capital, Inc. (IGC) has announced that its subsidiary, IGC Pharma, has entered into a cooperation agreement with Confiprosper Fintech Co., Ltd. This strategic partnership marks a significant step in IGC's global expansion plans, particularly in the pharmaceutical sector
1
.Expanding Market Reach
The collaboration between IGC Pharma and Confiprosper Fintech is set to open new doors for both companies. Confiprosper Fintech, with its established presence in Southeast Asia and Latin America, will provide IGC Pharma with valuable access to these markets. This move aligns with IGC's strategy to broaden its international footprint and tap into emerging pharmaceutical markets
1
.Focus on Alzheimer's Treatment
One of the key aspects of this partnership is the focus on IGC Pharma's flagship product, IGC-AD1. This investigational drug is currently undergoing Phase 2 clinical trials for the treatment of agitation in dementia due to Alzheimer's disease. The collaboration with Confiprosper Fintech is expected to accelerate the development and potential commercialization of IGC-AD1 in new markets
2
.Leveraging Fintech Expertise
Confiprosper Fintech brings to the table its expertise in financial technology and market access. This partnership is expected to facilitate smoother financial transactions and potentially streamline the process of bringing IGC Pharma's products to new markets. The fintech company's established networks in Southeast Asia and Latin America could prove instrumental in navigating regulatory landscapes and establishing distribution channels
1
.Related Stories
Potential Impact on Alzheimer's Treatment
The collaboration between IGC Pharma and Confiprosper Fintech holds promise for advancing Alzheimer's treatment options globally. With the increasing prevalence of Alzheimer's disease worldwide, expanding access to potential treatments like IGC-AD1 could have significant implications for patients and healthcare systems in Southeast Asia and Latin America
2
.Future Prospects
This strategic partnership represents a pivotal moment for IGC and its subsidiary, IGC Pharma. By joining forces with Confiprosper Fintech, the company is positioning itself for growth in key international markets. The success of this collaboration could pave the way for further expansion and potentially accelerate the development and distribution of innovative pharmaceutical solutions for neurodegenerative diseases
1
2
.References
Summarized by
Navi
Related Stories
Weekly Highlights
Weekly Highlights
Explore today's top stories
Your Daily Dose of Curated AI News
Don’t drown in AI news. We cut through the noise - filtering, ranking and summarizing the most important AI news, breakthroughs and research daily. Spend less time searching for the latest in AI and get straight to action.
